We launched our editorial advisory board in 2011, and since then, members have been connecting us with execs you want to read about. Take this month’s cover feature, and how that connection came about.

Considering we’ve received numerous questions regarding joining and working with corporate boards, we decided to create an expanded “Ask The Board” article for this month to serve as a resource to our readers.

Sometimes there is opportunity for leaders who show up when others don’t, such as building a reputation one is proud to have precede them.

In this edited transcript from our August 2021 executive virtual roundtable, perspectives on life science manufacturing and the supply chain are provided by three biopharma execs.

After working at Pfizer and being instrumental in the SpringWorks spinout, Lara Sullivan, M.D., is no stranger to building pharma companies. But getting to where she is today as CEO of Pyxis Therapeutics hasn’t come without its challenges.

The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.

With the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems leaders in biopharma manufacturing have never faced a greater challenge. Here’s what 12 of those execs have to say as they look to 2022 and beyond.

Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.

I predict the role played by the next generation of industry insiders will be what will forever change biopharma for the better.